Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Biosimilar drug is medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilar drug are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodys drugs production by bio-engineered technology, but does not include a vaccine.
As healthcare costs continue to rise, biosimilars offer new therapeutic options with the potential for cost savings to the healthcare system. With anticipated savings, biosimilars bring hope that there will be expanded access for patients to not only these known therapies, but also to new innovative medicines. At Biotech Pharma, serving patients is at the core of what we do and it is why we’re using our more than 35 years of biologics experience to develop high-quality biosimilars.First, in pharmerging markets, both governments and patients struggle to pay for biosimilars, which encouraged the demand of biosimilars, therefore in the future the biosimilars will grow around 20%.Second, generally, biosimilars industry is still in their infancy in China. It is commonly believed that the next 10 to 15 years is the golden period of the development of biosimilars. Third, for the biosimilars industry, technical barriers will be much smaller, in the next few years, there will be more and more enterprises going into biosimilars industry.Forth, most of biosimilars manufacturer are concentrated in US, Germany, UK and other developed countries. At last, through the research we tend to believe that the biosimilars, now is a chance for newcomers and they will greatly change the industry.
This report offers an overview of the market trends, drivers, and barriers with respect to the China Biosimilar Drug market. It also provides a detailed overview of the market of different regions across North China, Central China, South China, East China, Northeast China, Southwest China, Northwest China. The report deep analyzes type and application in China Biosimilar Drug market. Detailed analysis of key players, along with key growth strategies adopted by Biosimilar Drug industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.
By Player:
Biotech Pharma
Eli Lilly
CP Guojian Pharma
Amgen
Novartis
By Type:
Injection
Tablets
Other Types
By End-User:
Ankylosing Spondylitis
Tumor
Rheumatoid Arthrtis
Cardiovascular
Other Application
By Region:
-
North China
-
Central China
-
South China
-
East China
-
Northeast China
-
Southwest China
-
Northwest China
TABLE OF CONTENT
1 Report Overview
-
1.1 Product Definition and Scope
-
1.2 PEST (Political, Economic, Social and Technological) Analysis of Biosimilar Drug Market
-
1.3 Market Segment by Type
-
1.3.1 China Biosimilar Drug Market Size and Growth Rate of Injection from 2016 to 2027
-
1.3.2 China Biosimilar Drug Market Size and Growth Rate of Tablets from 2016 to 2027
-
1.3.3 China Biosimilar Drug Market Size and Growth Rate of Other Types from 2016 to 2027
-
1.4 Market Segment by Application
-
1.4.1 China Biosimilar Drug Market Size and Growth Rate of Ankylosing Spondylitis from 2016 to 2027
-
1.4.2 China Biosimilar Drug Market Size and Growth Rate of Tumor from 2016 to 2027
-
1.4.3 China Biosimilar Drug Market Size and Growth Rate of Rheumatoid Arthrtis from 2016 to 2027
-
1.4.4 China Biosimilar Drug Market Size and Growth Rate of Cardiovascular from 2016 to 2027
-
1.4.5 China Biosimilar Drug Market Size and Growth Rate of Other Application from 2016 to 2027
-
1.5 Market Segment by Regions
-
1.5.1 North China Biosimilar Drug Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.2 Central China Biosimilar Drug Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.3 South China Biosimilar Drug Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.4 East China Biosimilar Drug Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.5 Northeast China Biosimilar Drug Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.6 Southwest China Biosimilar Drug Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.7 Northwest China Biosimilar Drug Consumption Market Size and Growth Rate from 2016 to 2027
2 Market Trends and Competitive Landscape
-
2.1 Market Trends and Dynamics
-
2.1.1 Market Challenges and Restraints
-
2.1.2 Market Opportunities and Potentials
-
2.1.3 Mergers and Acquisitions
-
2.2 Competitive Landscape Analysis
-
2.2.1 Industrial Concentration Analysis
-
2.2.2 Porter's Five Forces Analysis of the Industry
-
2.2.3 SWOT Analysis for New Entrants
-
2.3 Coronavirus (COVID-19) Distribution and its Impact on the Industry
3 Segmentation of Biosimilar Drug Market by Types
-
3.1 Products Development Trends of Different Types
-
3.2 Commercial Products Types of Major Vendors
-
3.3 Competitive Landscape Analysis of Different Types
-
3.4 Market Size of Biosimilar Drug by Major Types
-
3.4.1 Market Size and Growth Rate of Injection
-
3.4.2 Market Size and Growth Rate of Tablets
-
3.4.3 Market Size and Growth Rate of Other Types
4 Segmentation of Biosimilar Drug Market by End-Users
-
4.1 Downstream Client Analysis by End-Users
-
4.2 Competitive Landscape Analysis of Different End-Users
-
4.3 Market Potential Analysis of Different End-Users
-
4.4 Market Size of Biosimilar Drug by Major End-Users
-
4.4.1 Market Size and Growth Rate of Biosimilar Drug in Ankylosing Spondylitis
-
4.4.2 Market Size and Growth Rate of Biosimilar Drug in Tumor
-
4.4.3 Market Size and Growth Rate of Biosimilar Drug in Rheumatoid Arthrtis
-
4.4.4 Market Size and Growth Rate of Biosimilar Drug in Cardiovascular
-
4.4.5 Market Size and Growth Rate of Biosimilar Drug in Other Application
5 Market Analysis by Regions
-
5.1 China Biosimilar Drug Production Analysis by Regions
-
5.2 China Biosimilar Drug Consumption Analysis by Regions
-
5.3 Coronavirus (COVID-19) Impact on China Economy
6 North China Biosimilar Drug Landscape Analysis
-
6.1 North China Biosimilar Drug Landscape Analysis by Major Types
-
6.2 North China Biosimilar Drug Landscape Analysis by Major End-Users
7 Central China Biosimilar Drug Landscape Analysis
-
7.1 Central China Biosimilar Drug Landscape Analysis by Major Types
-
7.2 Central China Biosimilar Drug Landscape Analysis by Major End-Users
8 South China Biosimilar Drug Landscape Analysis
-
8.1 South China Biosimilar Drug Landscape Analysis by Major Types
-
8.2 South China Biosimilar Drug Landscape Analysis by Major End-Users
9 East China Biosimilar Drug Landscape Analysis
-
9.1 East China Biosimilar Drug Landscape Analysis by Major Types
-
9.2 East China Biosimilar Drug Landscape Analysis by Major End-Users
10 Northeast China Biosimilar Drug Landscape Analysis
-
10.1 Northeast China Biosimilar Drug Landscape Analysis by Major Types
-
10.2 Northeast China Biosimilar Drug Landscape Analysis by Major End-Users
11 Southwest China Biosimilar Drug Landscape Analysis
-
11.1 Southwest China Biosimilar Drug Landscape Analysis by Major Types
-
11.2 Southwest China Biosimilar Drug Landscape Analysis by Major End-Users
12 Northwest China Biosimilar Drug Landscape Analysis
-
12.1 Northwest China Biosimilar Drug Landscape Analysis by Major Types
-
12.2 Northwest China Biosimilar Drug Landscape Analysis by Major End-Users
13 Major Players Profiles
-
13.1 Biotech Pharma
-
13.1.1 Biotech Pharma Company Profile and Recent Development
-
13.1.2 Market Performance
-
13.1.3 Product and Service Introduction
-
13.2 Eli Lilly
-
13.2.1 Eli Lilly Company Profile and Recent Development
-
13.2.2 Market Performance
-
13.2.3 Product and Service Introduction
-
13.3 CP Guojian Pharma
-
13.3.1 CP Guojian Pharma Company Profile and Recent Development
-
13.3.2 Market Performance
-
13.3.3 Product and Service Introduction
-
13.4 Amgen
-
13.4.1 Amgen Company Profile and Recent Development
-
13.4.2 Market Performance
-
13.4.3 Product and Service Introduction
-
13.5 Novartis
-
13.5.1 Novartis Company Profile and Recent Development
-
13.5.2 Market Performance
-
13.5.3 Product and Service Introduction
The List of Tables and Figures
-
Figure Product Picture
-
Figure China Biosimilar Drug Market Size and Growth Rate of Injection from 2016 to 2027
-
Figure China Biosimilar Drug Market Size and Growth Rate of Tablets from 2016 to 2027
-
Figure China Biosimilar Drug Market Size and Growth Rate of Other Types from 2016 to 2027
-
Figure Market Share by Type in 2016
-
Figure Market Share by Type in 2021
-
Figure Market Share by Type in 2027
-
Figure China Biosimilar Drug Market Size and Growth Rate of Ankylosing Spondylitis from 2016 to 2027
-
Figure China Biosimilar Drug Market Size and Growth Rate of Tumor from 2016 to 2027
-
Figure China Biosimilar Drug Market Size and Growth Rate of Rheumatoid Arthrtis from 2016 to 2027
-
Figure China Biosimilar Drug Market Size and Growth Rate of Cardiovascular from 2016 to 2027
-
Figure China Biosimilar Drug Market Size and Growth Rate of Other Application from 2016 to 2027
-
Figure Market Share by End-User in 2016
-
Figure Market Share by End-User in 2021
-
Figure Market Share by End-User in 2027
-
Figure North China Biosimilar Drug Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Central China Biosimilar Drug Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure South China Biosimilar Drug Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure East China Biosimilar Drug Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Northeast China Biosimilar Drug Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Southwest China Biosimilar Drug Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Northwest China Biosimilar Drug Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Development Trends and Industry Dynamics of Biosimilar Drug Industry
-
Figure Market Challenges and Restraints
-
Figure Market Opportunities and Potentials
-
Table Mergers and Acquisition
-
Figure Market Share of TOP 3 Players in 2020
-
Figure Market Share of TOP 5 Players in 2021
-
Figure Market Share of TOP 6 Players from 2016 to 2021
-
Figure Porter's Five Forces Analysis
-
Figure New Entrant SWOT Analysis
-
Figure Coronavirus (COVID-19) Map of China
-
Table Coronavirus (COVID-19) Impact on the Industry
-
Figure Specifications of Different Types of Biosimilar Drug
-
Figure Development Trends of Different Types
-
Table Commercial Products Types of Major Vendors
-
Figure Competitive Landscape Analysis of Different Types
-
Table Consumption of Biosimilar Drug by Different Types from 2016 to 2027
-
Table Consumption Share of Biosimilar Drug by Different Types from 2016 to 2027
-
Figure Market Size and Growth Rate of Injection
-
Figure Market Size and Growth Rate of Tablets
-
Figure Market Size and Growth Rate of Other Types
-
Table Downstream Client Analysis by End-Users
-
Figure Competitive Landscape Analysis of Different End-Users
-
Table Market Potential Analysis of Different End-Users
-
Figure Consumption of Biosimilar Drug by Different End-Users from 2016 to 2027
-
Table Consumption Share of Biosimilar Drug by Different End-Users from 2016 to 2027
-
Figure Market Size and Growth Rate of Ankylosing Spondylitis
-
Figure Market Size and Growth Rate of Tumor
-
Figure Market Size and Growth Rate of Rheumatoid Arthrtis
-
Figure Market Size and Growth Rate of Cardiovascular
-
Figure Market Size and Growth Rate of Other Application
-
Table China Biosimilar Drug Production by Regions
-
Table China Biosimilar Drug Production Share by Regions
-
Figure China Biosimilar Drug Production Share by Regions in 2016
-
Figure China Biosimilar Drug Production Share by Regions in 2021
-
Figure China Biosimilar Drug Production Share by Regions in 2027
-
Table China Biosimilar Drug Consumption by Regions
-
Table China Biosimilar Drug Consumption Share by Regions
-
Figure China Biosimilar Drug Consumption Share by Regions in 2016
-
Figure China Biosimilar Drug Consumption Share by Regions in 2021
-
Figure China Biosimilar Drug Consumption Share by Regions in 2027
-
Table North China Biosimilar Drug Consumption by Types from 2016 to 2027
-
Table North China Biosimilar Drug Consumption Share by Types from 2016 to 2027
-
Figure North China Biosimilar Drug Consumption Share by Types in 2016
-
Figure North China Biosimilar Drug Consumption Share by Types in 2021
-
Figure North China Biosimilar Drug Consumption Share by Types in 2027
-
Table North China Biosimilar Drug Consumption by End-Users from 2016 to 2027
-
Table North China Biosimilar Drug Consumption Share by End-Users from 2016 to 2027
-
Figure North China Biosimilar Drug Consumption Share by End-Users in 2016
-
Figure North China Biosimilar Drug Consumption Share by End-Users in 2021
-
Figure North China Biosimilar Drug Consumption Share by End-Users in 2027
-
Table Central China Biosimilar Drug Consumption by Types from 2016 to 2027
-
Table Central China Biosimilar Drug Consumption Share by Types from 2016 to 2027
-
Figure Central China Biosimilar Drug Consumption Share by Types in 2016
-
Figure Central China Biosimilar Drug Consumption Share by Types in 2021
-
Figure Central China Biosimilar Drug Consumption Share by Types in 2027
-
Table Central China Biosimilar Drug Consumption by End-Users from 2016 to 2027
-
Table Central China Biosimilar Drug Consumption Share by End-Users from 2016 to 2027
-
Figure Central China Biosimilar Drug Consumption Share by End-Users in 2016
-
Figure Central China Biosimilar Drug Consumption Share by End-Users in 2021
-
Figure Central China Biosimilar Drug Consumption Share by End-Users in 2027
-
Table South China Biosimilar Drug Consumption by Types from 2016 to 2027
-
Table South China Biosimilar Drug Consumption Share by Types from 2016 to 2027
-
Figure South China Biosimilar Drug Consumption Share by Types in 2016
-
Figure South China Biosimilar Drug Consumption Share by Types in 2021
-
Figure South China Biosimilar Drug Consumption Share by Types in 2027
-
Table South China Biosimilar Drug Consumption by End-Users from 2016 to 2027
-
Table South China Biosimilar Drug Consumption Share by End-Users from 2016 to 2027
-
Figure South China Biosimilar Drug Consumption Share by End-Users in 2016
-
Figure South China Biosimilar Drug Consumption Share by End-Users in 2021
-
Figure South China Biosimilar Drug Consumption Share by End-Users in 2027
-
Table East China Biosimilar Drug Consumption by Types from 2016 to 2027
-
Table East China Biosimilar Drug Consumption Share by Types from 2016 to 2027
-
Figure East China Biosimilar Drug Consumption Share by Types in 2016
-
Figure East China Biosimilar Drug Consumption Share by Types in 2021
-
Figure East China Biosimilar Drug Consumption Share by Types in 2027
-
Table East China Biosimilar Drug Consumption by End-Users from 2016 to 2027
-
Table East China Biosimilar Drug Consumption Share by End-Users from 2016 to 2027
-
Figure East China Biosimilar Drug Consumption Share by End-Users in 2016
-
Figure East China Biosimilar Drug Consumption Share by End-Users in 2021
-
Figure East China Biosimilar Drug Consumption Share by End-Users in 2027
-
Table Northeast China Biosimilar Drug Consumption by Types from 2016 to 2027
-
Table Northeast China Biosimilar Drug Consumption Share by Types from 2016 to 2027
-
Figure Northeast China Biosimilar Drug Consumption Share by Types in 2016
-
Figure Northeast China Biosimilar Drug Consumption Share by Types in 2021
-
Figure Northeast China Biosimilar Drug Consumption Share by Types in 2027
-
Table Northeast China Biosimilar Drug Consumption by End-Users from 2016 to 2027
-
Table Northeast China Biosimilar Drug Consumption Share by End-Users from 2016 to 2027
-
Figure Northeast China Biosimilar Drug Consumption Share by End-Users in 2016
-
Figure Northeast China Biosimilar Drug Consumption Share by End-Users in 2021
-
Figure Northeast China Biosimilar Drug Consumption Share by End-Users in 2027
-
Table Southwest China Biosimilar Drug Consumption by Types from 2016 to 2027
-
Table Southwest China Biosimilar Drug Consumption Share by Types from 2016 to 2027
-
Figure Southwest China Biosimilar Drug Consumption Share by Types in 2016
-
Figure Southwest China Biosimilar Drug Consumption Share by Types in 2021
-
Figure Southwest China Biosimilar Drug Consumption Share by Types in 2027
-
Table Southwest China Biosimilar Drug Consumption by End-Users from 2016 to 2027
-
Table Southwest China Biosimilar Drug Consumption Share by End-Users from 2016 to 2027
-
Figure Southwest China Biosimilar Drug Consumption Share by End-Users in 2016
-
Figure Southwest China Biosimilar Drug Consumption Share by End-Users in 2021
-
Figure Southwest China Biosimilar Drug Consumption Share by End-Users in 2027
-
Table Northwest China Biosimilar Drug Consumption by Types from 2016 to 2027
-
Table Northwest China Biosimilar Drug Consumption Share by Types from 2016 to 2027
-
Figure Northwest China Biosimilar Drug Consumption Share by Types in 2016
-
Figure Northwest China Biosimilar Drug Consumption Share by Types in 2021
-
Figure Northwest China Biosimilar Drug Consumption Share by Types in 2027
-
Table Northwest China Biosimilar Drug Consumption by End-Users from 2016 to 2027
-
Table Northwest China Biosimilar Drug Consumption Share by End-Users from 2016 to 2027
-
Figure Northwest China Biosimilar Drug Consumption Share by End-Users in 2016
-
Figure Northwest China Biosimilar Drug Consumption Share by End-Users in 2021
-
Figure Northwest China Biosimilar Drug Consumption Share by End-Users in 2027
-
Table Company Profile and Development Status of Biotech Pharma
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Biotech Pharma
-
Figure Sales and Growth Rate Analysis of Biotech Pharma
-
Figure Revenue and Market Share Analysis of Biotech Pharma
-
Table Product and Service Introduction of Biotech Pharma
-
Table Company Profile and Development Status of Eli Lilly
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Eli Lilly
-
Figure Sales and Growth Rate Analysis of Eli Lilly
-
Figure Revenue and Market Share Analysis of Eli Lilly
-
Table Product and Service Introduction of Eli Lilly
-
Table Company Profile and Development Status of CP Guojian Pharma
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of CP Guojian Pharma
-
Figure Sales and Growth Rate Analysis of CP Guojian Pharma
-
Figure Revenue and Market Share Analysis of CP Guojian Pharma
-
Table Product and Service Introduction of CP Guojian Pharma
-
Table Company Profile and Development Status of Amgen
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Amgen
-
Figure Sales and Growth Rate Analysis of Amgen
-
Figure Revenue and Market Share Analysis of Amgen
-
Table Product and Service Introduction of Amgen
-
Table Company Profile and Development Status of Novartis
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Novartis
-
Figure Sales and Growth Rate Analysis of Novartis
-
Figure Revenue and Market Share Analysis of Novartis
-
Table Product and Service Introduction of Novartis
-
